By continuing to delay significant reductions in greenhouse gas emissions, we risk handing young people alive today a bill of up to US$535 trillion. This would be the cost of the “negative emissions” technologies required to remove CO₂ from the air in order to avoid dangerous climate change.
These are the main findings of new research published in Earth System Dynamics, conducted by an international team led by US climate scientist James Hansen, previously the director of NASA’s Goddard Institute for Space Studies.
JNJ is covered by 9 analysts who by consensus are expecting a 30.6% increase in earnings over the next 3 years. This would see the EPS rise to $8.07 levels which would no doubt please investors who are used to an average of $5.75 over the past few years.
This will project the annual earnings to levels above what has been seen in the past few years.
During the same time revenue is predicted to grow from $72.17 Billion to $84.38 Billion in 2020 and profit is predicted to escalate from $16.50 Billion to $22.89 Billion in 2020, roughly growing 1.4x. Margins are expected to be extremely healthy during this time as well.
By blocking of an enzyme that affects the cellular microenvironment it is possible to stop brain tumour cells from growing. This is shown in a new study published in the journal Molecular Cancer Therapeutics by researchers at Uppsala University in collaboration with researchers in Haifa, Israel and Brisbane, Australia.
Brain tumours constitute 25% of all childhood cancers. Among those are malignant forms such as medulloblastoma, a cancer of the cerebellum.
The benefits of trade
The tradable sector directly and indirectly accounts for $85 billion (43%) of New Zealand’s real GDP and almost three-quarters of a million jobs.
Trade helps Kiwi households buy higher quantities of goods and services with their wages, and lets them access a wider variety of products.
The gains to New Zealand households from improved product choice from trade alone come to $3.9 billion, or around $2,300 per household, based on estimates from the literature
Verily, the life sciences branch of Alphabet (Google’s parent company), has started releasing millions of mosquitoes in California.
The team behind the project — made up of scientists from Verily, biotech company MosquitoMate, and Fresno County’s Consolidated Mosquito Abatement District — plans to set a million of the flying insects free each week for 20 weeks.
The mosquitoes are being released into two neighbourhoods in Fresno, California as part of a field study for the Debug Project, an initiative that aims tor decimate certain mosquito populations.
For big drugmakers that want to grow their business, acquiring smaller companies with one or two products is often a surefire way to make sure that happens.
But in the past few years, we’ve seen a slowdown in M&A, with acquisitions in the first quarter of 2017 down 35% from the same period two years ago.
Flemming Ornskov, the CEO of $US50 billion drugmaker Shire which had one of the biggest pharma mergers in recent history with the $US32 billion acquisition of Baxalta at the very start of 2016, said he knows there’s been less M&A than usual.
Hawke’s Bay-based national company StockX won the prestigious Tru-Test Innovation Award at the Beef + Lamb NZ Sheep Industry Awards held in Invercargill last week.
StockX is an online service that enables farmers to trade stock directly with other farmers nationally.
Sales and Marketing Manager Emma Oliver said it was great to be recognised “for the value we are delivering to the market through innovation”.
Taking place in Auckland’s Viaduct Events Centre on Thursday evening, the event brought together some of the best and brightest scientists, researchers and academics in the Land of the Long White Cloud.
Among the highlights of the evening was a speech by Cather Simpson, University of Auckland Professor of Chemistry & Physics, Director of the Photon Factory, and CSO of Engender Tech – not to mention the Supreme Award winner at last year’s event. She spoke about the importance of never giving up despite the odds, but also of aiming high.
UDG Healthcare plc (‘the Group’), a leading international healthcare services provider, is pleased to announce the acquisition of Vynamic LLC, a US-based healthcare industry management consulting firm, for a total consideration of up to $32m.
Vynamic is headquartered in Philadelphia and its primary service offerings include: brand strategy, planning and launch, advanced commercial operations capabilities, strategic transformation and integration, product design and implementation, change leadership and business intelligence and analytics.
A group of cancer experts started weighing Wednesday whether to recommend U.S. regulatory approval for a first-of-its kind gene therapy targeting an aggressive form of leukemia that occurs in children and young adults.
The treatment, called CTL019 and developed by Swiss drug giant Novartis AG, works by modifying a patient’s own immune cells to make them more effective at hunting down and killing tumor cells. It involves removing some of the patient’s blood and genetically modifying the T-cells, a type of immune cell, before re-infusion.